Vyndaqel 20 mg/1
tafamidis meglumine · CAPSULE, LIQUID FILLED · Pfizer Laboratories Div Pfizer Inc
Vyndaqel (tafamidis meglumine) is an oral medication taken as a capsule that is used to treat a rare condition called transthyretin amyloidosis, which affects the heart and nervous system. It works by stabilizing a protein in the body that would otherwise accumulate and cause organ damage.
Key Facts
- Brand Name
- Vyndaqel
- Generic Name
- tafamidis meglumine
- NDC Code (Product)
0069-1975- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Strength
- 20 mg/1
- Dosage Form
- CAPSULE, LIQUID FILLED
- Route
- ORAL
- Marketing Status
- Application #
- NDA211996
- Marketing Start
- 05/16/2019
Recall History
No Recall HistoryFrequently Asked Questions
What is Vyndaqel used for?
Vyndaqel (tafamidis meglumine) is an oral medication taken as a capsule that is used to treat a rare condition called transthyretin amyloidosis, which affects the heart and nervous system. It works by stabilizing a protein in the body that would otherwise accumulate and cause organ damage.
Is Vyndaqel a controlled substance?
Vyndaqel is not classified as a controlled substance by the DEA.
What is the generic name for Vyndaqel?
The generic name for Vyndaqel is tafamidis meglumine. There are no other listed brand versions of tafamidis meglumine.
What is the NDC code for Vyndaqel 20 mg/1?
The NDC (National Drug Code) for Vyndaqel 20 mg/1 is 0069-1975, listed by Pfizer Laboratories Div Pfizer Inc.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)